drugset / Trial / NCT00521950

Cost-effectiveness of TPMT Pharmacogenetics

NCT00521950 ↗

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT) genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel disease (IBD) in need of immune suppression. The study is designed to test the hypothesis that optimization of initial thiopurine dose based on pre-treatment TPMT genotyping will maximize treatment efficacy and minimize adverse drug reactions (ADRs) resulting in reduced costs.

Timeline

Start
2007-09
Primary completion
2011-12
Completion
2011-12

Outcome

Missed primary endpoint

paper Similar proportions of patients in the intervention and control groups developed a hematologic ADR (7.4% vs 7.9%; relative risk, 0.93; 95% confidence interval, 0.57-1.52) PMID 26072396 ↗

paper the groups also had similar mean levels of disease activity (P = .18 for Crohn's disease and P = .14 for ulcerative colitis). PMID 26072396 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Azathioprine Small molecule — —
Subject MERCAPTOPURINE ANHYDROUS Small molecule — —